These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Structural difference of vasoactive intestinal peptide in two distinct membrane-mimicking environments. Umetsu Y; Tenno T; Goda N; Shirakawa M; Ikegami T; Hiroaki H Biochim Biophys Acta; 2011 May; 1814(5):724-30. PubMed ID: 21439408 [TBL] [Abstract][Full Text] [Related]
4. VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1. Shi H; Carion TW; Jiang Y; Steinle JJ; Berger EA Prostaglandins Other Lipid Mediat; 2016 Mar; 123():28-32. PubMed ID: 27026343 [TBL] [Abstract][Full Text] [Related]
5. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination. Trent A; Ulery BD; Black MJ; Barrett JC; Liang S; Kostenko Y; David NA; Tirrell MV AAPS J; 2015 Mar; 17(2):380-8. PubMed ID: 25527256 [TBL] [Abstract][Full Text] [Related]
6. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506 [TBL] [Abstract][Full Text] [Related]
7. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. Li JM; Darlak KA; Southerland L; Hossain MS; Jaye DL; Josephson CD; Rosenthal H; Waller EK PLoS One; 2013; 8(5):e63381. PubMed ID: 23723978 [TBL] [Abstract][Full Text] [Related]
8. Instructive Design of Triblock Peptide Amphiphiles for Structurally Complex Micelle Fabrication. Zhang R; Morton LD; Smith JD; Gallazzi F; White TA; Ulery BD ACS Biomater Sci Eng; 2018 Jul; 4(7):2330-2339. PubMed ID: 33435099 [TBL] [Abstract][Full Text] [Related]
9. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. Fabricius D; O'Dorisio MS; Blackwell S; Jahrsdörfer B J Immunol; 2006 Nov; 177(9):5920-7. PubMed ID: 17056516 [TBL] [Abstract][Full Text] [Related]
10. Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles. Eskandari Z; Bahadori F; Yapaoz MA; Yenigun VB; Celikten M; Kocyigit A; Onyuksel H Eur J Pharm Sci; 2021 Jul; 162():105830. PubMed ID: 33819623 [TBL] [Abstract][Full Text] [Related]
11. Multifunctional Self-Assembling Peptide-Based Nanostructures for Targeted Intracellular Delivery: Design, Physicochemical Characterization, and Biological Assessment. Shi Y; Lin R; Cui H; Azevedo HS Methods Mol Biol; 2018; 1758():11-26. PubMed ID: 29679319 [TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516 [TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism. Huang L; Tang Y; Qin J; Peng Y; Yuan Q; Zhang F; Tao L Inflammation; 2012 Jun; 35(3):1154-60. PubMed ID: 22207455 [TBL] [Abstract][Full Text] [Related]
14. Lipidated gemini peptide amphiphiles with enhanced loading capacity and cell membrane affinity for drug delivery. Yin X; Chen Z; Chen Y; Xie Y; Xiong B; Jiang H; Zhu J Colloids Surf B Biointerfaces; 2020 Nov; 195():111271. PubMed ID: 32736122 [TBL] [Abstract][Full Text] [Related]
15. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles. Ashok B; Rubinstein I; Tsueshita T; Onyüksel H Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692 [TBL] [Abstract][Full Text] [Related]
16. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Ganea D Adv Neuroimmunol; 1996; 6(1):61-74. PubMed ID: 8790782 [TBL] [Abstract][Full Text] [Related]
17. Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease. Jayawardena D; Anbazhagan AN; Guzman G; Dudeja PK; Onyuksel H Mol Pharm; 2017 Nov; 14(11):3698-3708. PubMed ID: 28991483 [TBL] [Abstract][Full Text] [Related]